Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON and PHILADELPHIA - Avacta Therapeutics (AIM:AVCT), a developer of targeted oncology drugs, has made its Annual Report for the year ended December 31, 2024, publicly accessible and announced a rescheduled date for its Annual General Meeting (AGM). The report is now available on the company’s investor website, and the AGM, previously set for June 30, 2025, will now take place on Wednesday, July 2, 2025, at 9:00 am BST.
The venue for the AGM is Peel Hunt LLP’s offices on Liverpool Street in London, with a capacity for approximately 120 attendees. Avacta has requested shareholders wishing to attend in person to pre-register by June 27, 2025, although this is not a requirement for admission. The company will prioritize registered shareholders for voting purposes, and details on proxy voting are included in the AGM notice.
Following the AGM, Avacta will provide a business update, which will be recorded and made available on their website for those not attending. All presentation materials will also be accessible online at the end of the day, with the assurance that no new material information will be disclosed.
The company has advised early pre-registration for the AGM due to limited space and will manage non-registered shareholder attendance on a first-come, first-served basis. Attendees are recommended to arrive early to comply with admission procedures.
This information is based on a press release statement from Avacta Group plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.